<DOC>
	<DOCNO>NCT02282930</DOCNO>
	<brief_summary>This study design answer whether patient progressive IgA nephropathy , receive Acthar ( ACTH ) gel injection dose 80 unit subcutaneously twice weekly 6 month effective induce improvement proteinuria renal function .</brief_summary>
	<brief_title>Pilot Study ACTH Treatment IgA Nephropathy High Risk Progression</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Inclusion : Proteinuria &gt; 1000 mg/24h despite documented ACEi/ARB therapy adequate blood pressure control &gt; 3 month . Quantified 24h creatinine clearance &gt; 30 ml/min/1.73m2 . Blood pressure &lt; 130/80 mmHg &gt; 75 % reading . Henoch Schoenlein Purpura ( HSP ) : Patients biopsy proven IgA nephropathy clinical feature consistent Henoch Schonlein Purpura consider eligible study . Patient must able receive injection enrol study . Patient must kidney biopsy slide file send Mayo Clinic . Exclusion : Clinical histologic evidence IgA predominant Lupus nephritis Patients great 50 % glomerular senescence cortical scar renal biopsy . Serum Cr &gt; 3.0 mg/dL creatinine clearance GFR &lt; 30 ml/min time screen Patients history Crohn 's disease Celiac Sprue Clinical evidence cirrhosis , chronic active liver disease . Known infection hepatitis B , hepatitis C , HIV ( Patients serologically screen prior study entry ( rest complete last two year , patient undergo additional testing ) . Active systemic infection bacterial , viral , fungal , mycobacterial atypical mycobacterial infection ( exclude fungal infection nail bed ) . Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week prior screen . Positive pregnancy test breast feeding time study entry ( urine pregnancy test perform woman childbearing potential later 7 day prior treatment ) patient unwilling comply contraceptive measure outline . Patients receive therapy oral prednisone glucocorticoid equivalent past 3 month . Patients receive immunosuppressive therapy include cyclophosphamide , MMF , cyclosporine , tacrolimus azathioprine last 6 month . Current recent ( within 30 day ) exposure investigational drug . Patients receive live vaccine within 28 day study enrollment . Hemoglobin : &lt; 8.5 gm/dL Platelets : &lt; 100,000/mm AST ALT &gt; 2.5 x Upper Limit Normal Patients anaphylaxis and/or know allergic reaction ACTH Previous Treatment ACTH History drug , alcohol , chemical abuse within 6 month prior screen Concomitant previous malignancy , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . History psychiatric disorder would interfere normal participation protocol . Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ACTH</keyword>
	<keyword>Acthar</keyword>
	<keyword>IgA</keyword>
	<keyword>Progressive</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>renal function</keyword>
</DOC>